The Prostate Cancer Foundation (PCF) today announced a $10 million unrestricted gift from an anonymous donor to launch a ...
Longitudinal PRO modeling, rather than time-to-worsening censoring, indicated maintained HRQOL and pain outcomes with radioligand intensification despite early on-treatment score fluctuations. FACT-P ...
PSMA-617 to androgen deprivation therapy (ADT) with androgen receptor pathway inhibitor (ARPI) bettered disease control in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according ...
The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being ...
Pooled trials show Pluvicto improves progression-free survival in advanced prostate cancer, without increasing serious adverse events. An examination of data from more than 2500 patients with advanced ...
The Prostate Cancer Foundation (PCF) today announced a $10 million unrestricted gift from an anonymous donor to launch a TACTICAL (Therapy ACceleration To Intercept CAncer Lethality) Award, which will ...
The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing ...
Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting ...
The main market opportunities lie in the commercialization and development of PSMA-targeted therapies and radiodiagnostics for prostate cancer. Key areas include expansion in radioligand therapy and ...
Novartis today announced multiple US real-world studies delivering new insights across metastatic prostate cancer care. The analyses utilize data from Novartis’ PRECISION platform to evaluate ...
For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials
Real-world PRECISION data in 500 taxane-naïve, PSMA-positive mCRPC patients showed median PFS 13.5 months (95% CI, 11.7–14.7), aligning with PSMAfore efficacy expectations. Earlier sequencing mattered ...
Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results